[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Iovance Biotherapeutics Inc (IOVA)

Iovance Biotherapeutics Inc (IOVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,830,823
  • Shares Outstanding, K 446,502
  • Annual Sales, $ 263,500 K
  • Annual Income, $ -390,980 K
  • EBIT $ -319 M
  • EBITDA $ -279 M
  • 60-Month Beta 0.71
  • Price/Sales 10.52
  • Price/Cash Flow N/A
  • Price/Book 3.84

Options Overview Details

View History
  • Implied Volatility 93.42% (-8.35%)
  • Historical Volatility 135.51%
  • IV Percentile 11%
  • IV Rank 5.93%
  • IV High 842.11% on 08/26/25
  • IV Low 46.25% on 10/14/25
  • Expected Move (DTE 5) 0.72 (11.40%)
  • Put/Call Vol Ratio 0.28
  • Today's Volume 20,996
  • Volume Avg (30-Day) 14,104
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 286,716
  • Open Int (30-Day) 260,390
  • Expected Range 5.62 to 7.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.14
  • Number of Estimates 3
  • High Estimate $-0.12
  • Low Estimate $-0.15
  • Prior Year $-0.25
  • Growth Rate Est. (year over year) +44.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.76 +68.62%
on 07/15/26
6.92 -8.38%
on 08/07/26
+1.99 (+45.75%)
since 07/07/26
3-Month
3.28 +93.29%
on 05/19/26
6.92 -8.38%
on 08/07/26
+2.79 (+78.59%)
since 05/07/26
52-Week
1.76 +260.23%
on 11/05/25
6.92 -8.38%
on 08/07/26
+3.70 (+140.15%)
since 08/07/25

Most Recent Stories

More News
Iovance Biotherapeutics: Q2 Earnings Snapshot

Iovance Biotherapeutics: Q2 Earnings Snapshot

IOVA : 6.34 (+2.09%)
Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates

U.S. Amtagvi Revenue Reaches ~$91M and Total Revenue Increased 66% Year-over-Year Gross Margin Increased to 56% Fast Track Designation (FTD) Granted by the FDA for Lifileucel in Soft Tissue Sarcomas...

IOVA : 6.34 (+2.09%)
Iovance Biotherapeutics Reports Tomorrow With No Room Left Between Forecast and Commercialization Reality

Barchart Research What to Expect from IOVA Earnings IOVA Generated August 5, 2026 Current Price $4.34 EPS Estimate $$-0.17 Consensus Rating Moderate Buy Average Move 15.85% Iovance Biotherapeutics Reports...

IOVA : 6.34 (+2.09%)
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026

SAN CARLOS, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating...

IOVA : 6.34 (+2.09%)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering...

IOVA : 6.34 (+2.09%)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering...

IOVA : 6.34 (+2.09%)
Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE...

IOVA : 6.34 (+2.09%)
Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001

Next-Generation Platform Expands into Solid Tumors  Representing 100,000+ U.S. Deaths Annually SAN CARLOS, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA),...

IOVA : 6.34 (+2.09%)
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering...

IOVA : 6.34 (+2.09%)
Iovance Biotherapeutics to Present at Upcoming Conference

SAN CARLOS, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating...

IOVA : 6.34 (+2.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own...

See More

Key Turning Points

3rd Resistance Point 7.92
2nd Resistance Point 7.42
1st Resistance Point 6.88
Last Price 6.34
1st Support Level 5.84
2nd Support Level 5.34
3rd Support Level 4.80

See More

52-Week High 6.92
Last Price 6.34
Fibonacci 61.8% 4.95
Fibonacci 50% 4.34
Fibonacci 38.2% 3.73
52-Week Low 1.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.